Study aim: Comparison of the effect of remifentanil and dexmedetomidine on surgeon satisfaction from surgical field and bleeding in rhinoplasty Design: Double-blind randomized clinical trial Settings and conduct: The drugs are prepared in the operating room by a nurse who is unaware of the type of study with label A in the dexmedetomidine group and label B in the remifentanil group and are given to a person who is unaware of the specialization of the groups for injection. The person assessing patients and patient satisfaction at the end of the study is also unaware of the allocation of study groups. Participants/Inclusion and exclusion criteria: Inclusion criteria:18-45 y/o, Patients undergoing rhinoplasty surgery Exclusion criteria: Patients with liver dysfunction, Renal dysfunction, Any known allergy or hypersensitivity to study drugs, analgesics abuse, opium addiction, Diabetes , Hemorrhagic disease, Using anticoagulants, Cerebrovascular disease, Heart block, Cardiovascular disease. Intervention groups: In the Intervention group one patients will receive 1 μg / kg dexmedetomidine (PFIZER, USA) for 20 minutes and at the same time as induction begins with a dose of 0.6 μg / kg and continues until the end of the operation. In the Intervention group two simultaneously with the induction of anesthesia, in the remifentanil group (EXIR, IRAN), remifentanil infusion of 0.25 μg is started. It continued until the end of the operation. Main outcome variables: Intraoperative bleeding, pain,surgeon satisfaction